CYTOKINETICS, INCORPORATED Amortization of Debt Issuance Costs
CYTOKINETICS, INCORPORATED (CYTK) reported Amortization of Debt Issuance Costs of $112.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2022-02-25
- CYTOKINETICS, INCORPORATED amortization of debt issuance costs for the quarter ending 2021-12-31 was $26.00K.
- CYTOKINETICS, INCORPORATED amortization of debt issuance costs for the quarter ending 2021-09-30 was $30.00K, a 50.00% increase year-over-year.
- CYTOKINETICS, INCORPORATED amortization of debt issuance costs for the quarter ending 2021-06-30 was $29.00K, a 52.63% increase year-over-year.
- CYTOKINETICS, INCORPORATED amortization of debt issuance costs for the quarter ending 2021-03-31 was $27.00K, a 50.00% increase year-over-year.
- CYTOKINETICS, INCORPORATED amortization of debt issuance costs for fiscal 2021 was $112.00K, a 41.77% increase from fiscal 2020.
- CYTOKINETICS, INCORPORATED amortization of debt issuance costs for fiscal 2020 was $79.00K, a 19.70% increase from fiscal 2019.
- CYTOKINETICS, INCORPORATED amortization of debt issuance costs for fiscal 2019 was $66.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $26.00K derived: 10-K 12 month − 3 quarters · filed 2022-02-25 | $56.00K derived: sum of 2 quarters · filed 2022-02-25 | $85.00K derived: sum of 3 quarters · filed 2022-02-25 | $112.00K 10-K · filed 2022-02-25 |
| 2021-09-30 | $30.00K 10-Q · filed 2021-11-05 | $59.00K derived: sum of 2 quarters · filed 2021-11-05 | $86.00K derived: sum of 3 quarters · filed 2021-11-05 | |
| 2021-06-30 | $29.00K 10-Q · filed 2021-11-05 | $56.00K derived: sum of 2 quarters · filed 2021-11-05 | ||
| 2021-03-31 | $27.00K 10-Q · filed 2021-11-05 | |||
| 2020-12-31 | $79.00K 10-K · filed 2022-02-25 | |||
| 2020-09-30 | $20.00K 10-Q · filed 2021-11-05 | $39.00K derived: sum of 2 quarters · filed 2021-11-05 | $57.00K derived: sum of 3 quarters · filed 2021-11-05 | |
| 2020-06-30 | $19.00K 10-Q · filed 2021-11-05 | $37.00K derived: sum of 2 quarters · filed 2021-11-05 | ||
| 2020-03-31 | $18.00K 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $66.00K 10-K · filed 2021-02-26 | |||
| 2019-09-30 | $17.00K 10-Q · filed 2020-11-06 | $33.00K derived: sum of 2 quarters · filed 2020-11-06 | $49.00K derived: sum of 3 quarters · filed 2020-11-06 | |
| 2019-06-30 | $16.00K 10-Q · filed 2020-11-06 | $32.00K derived: sum of 2 quarters · filed 2020-11-06 | ||
| 2019-03-31 | $16.00K 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |